drugset / Trial / NCT03164655

Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network

NCT03164655

Phase 2 Completed 20 enrolled UNICANCER
RandomizedParallel-groupDouble-blindTreatment

Summary

National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only colorectal metastases (CRLM) considered still non resectable after at least two months of systemic induction chemotherapy.

Timeline

Start
2018-07-25
Primary completion
2021-07-15
Completion
2021-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 100 mg/m2 Other
Background Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Background Cetuximab Monoclonal antibody 500 mg/m2 Intravenous
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Panitumumab Monoclonal antibody 6 mg/kg Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous